Nautilus Biotechnology Inc (NAUT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.29-2.55%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NAUT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
NAUT — debt issuance
Dated 2026-09-11
Entry into a Material Definitive Agreement. On September 11, 2026, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA), LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000, from time to time, through an “at the market” offering program under which TD Cowen will act as sales agent. Under the Sales Agreement,…
Why it matters: The AKT1 assay tests whether Tau assay results can repeat on another target. Wider assay access could support the proteoform plan.
Supportive ifNautilus opens AKT1 to Early Access customers. Its results match the Tau assay's performance.
Worry ifAKT1 Early Access does not begin, or new data show performance below the Tau assay profile.
Why it matters: Voyager is not yet for sale. On-time shipments would mark a key step toward commercial use.
Supportive ifBy mid-2027, Nautilus says Voyager instrument shipments have started. Its planned launch remains on schedule.
Worry ifNautilus delays instrument shipments past mid-2027 or says key development work is not done.
Why it matters: The four-year study brings Voyager into Alzheimer’s and cancer research. Nautilus said it may receive up to $6 million.
Supportive ifNautilus reports SEEDS work is under way and confirms it receives the full $6 million in stated funding.
Worry ifNautilus reports that SEEDS funding is reduced, delayed, or ended, or that the planned work does not proceed.
Why it matters: The September filing allows stock sales of up to $125 million. Such sales could add shares while Nautilus funds development.
Worry ifA company filing reports common stock sold under the new program, with disclosed proceeds and share counts.
Less concerning ifA later filing confirms no shares were sold under the new program through that reporting period.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$450 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,164 loss on $10,000 · 11.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,844 loss on $10,000 · 78.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.